Stereotaxis, Inc. (STXS)
| Market Cap | 125.53M -39.2% |
| Revenue (ttm) | 31.20M +13.4% |
| Net Income | -22.95M |
| EPS | -0.24 |
| Shares Out | 99.63M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 719,853 |
| Open | 1.330 |
| Previous Close | 1.330 |
| Day's Range | 1.240 - 1.350 |
| 52-Week Range | 1.240 - 3.590 |
| Beta | 1.34 |
| Analysts | Buy |
| Price Target | 4.13 (+227.78%) |
| Earnings Date | Aug 11, 2026 |
About STXS
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. The company offers robotic magnetic navigation (RMN) systems, such as Genesis RMN, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites; and GenesisX RMN System, which is designed to enhance the accessibility of Robotic Magnetic Na... [Read more]
Financial Performance
In 2025, Stereotaxis's revenue was $32.38 million, an increase of 20.28% compared to the previous year's $26.92 million. Losses were -$22.91 million, -9.62% less than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for STXS stock is "Buy." The 12-month stock price target is $4.13, which is an increase of 227.78% from the latest price.
News
Stereotaxis to Report Second Quarter 2026 Financial Results on August 11, 2026
ST. LOUIS, July 21, 2026 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it ...
University of Szeged Pioneers First Robotic Cardiology Program in Hungary
First Robotic Magnetic Navigation system installed in Hungary University of Szeged, led by Cardiology Chief Dr. Szili-Torok, expected to treat hundreds of patients annually with all forms of cardiac a...
Stereotaxis files to sell 108.87M shares of common stock for holders
17:27 EDT Stereotaxis (STXS) files to sell 108.87M shares of common stock for holders
Stereotaxis files to sell 19.45M shares of common stock for holders
17:23 EDT Stereotaxis (STXS) files to sell 19.45M shares of common stock for holders
Stereotaxis Registration statement: Registration filing
Stereotaxis filed a registration statement on July 15, 2026, providing details about a securities offering with the SEC.
Stereotaxis Registration statement: Registration filing
Stereotaxis filed a registration statement on July 15, 2026, providing details about a securities offering with the SEC.
Stereotaxis Completes Acquisition of Robocath
ST. LOUIS and ROUEN, France, July 09, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announ...
Stereotaxis management to meet with BTIG
Meeting to be held in New York on July 7-10 hosted by BTIG.
Stereotaxis Slides: Investor presentation
Stereotaxis has posted slides in relation to its latest quarterly earnings report, which was published on June 23, 2026.
Stereotaxis price target lowered to $3.50 from $4 at Piper Sandler
Piper Sandler lowered the firm’s price target on Stereotaxis (STXS) to $3.50 from $4 and keeps an Overweight rating on the shares following quarterly results. Stereotaxis noted some headwinds to…
Stereotaxis Earnings Call Transcript: Q1 2026
Q1 2026 saw revenue decline due to transition from legacy products, but regulatory approvals and new product launches signal a foundational shift. Strong demand for new catheters and digital systems, plus the Robocath acquisition, support double-digit revenue growth guidance for 2026.
Stereotaxis Earnings release: Q1 2026
Stereotaxis released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Stereotaxis Quarterly report: Q1 2026
Stereotaxis has published its Q1 2026 quarterly earnings report on May 12, 2026.
Stereotaxis Reports 2026 First Quarter Financial Results & Business Updates
ST. LOUIS, May 12, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported business updates...
Stereotaxis Announces First MAGiC Procedures in the United States
ST. LOUIS, April 22, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the first pat...
Stereotaxis to Report First Quarter 2026 Financial Results on May 12, 2026
ST. LOUIS, April 21, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will ...
Stereotaxis Transcript: M&A announcement
The acquisition of Robocath brings complementary robotic technology, accelerating the strategy to lead in endovascular procedures. The deal includes up to $45 million in payments, targets a $20–30 billion market, and expects break-even by year three post-close.
Stereotaxis Press release: M&A announcement
Stereotaxis issued a press release on April 15, 2026, disclosing material business information to investors.
Stereotaxis to acquire Robocath, terms undisclosed
Stereotaxis (STXS) announced that it has entered into a definitive agreement to acquire Robocath. Stereotaxis estimates that Robocath will contribute approximately $2M in annual revenue during the fir...
Stereotaxis Announces Definitive Agreement to Acquire Robocath
ST. LOUIS and ROUEN, France, April 15, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today annou...
Stereotaxis receives FDA clearance for Synchrony system
Stereotaxis (STXS) announced that it has received FDA 510(k) clearance for the Synchrony system. “Synchrony and SynX are central to our digital surgery efforts to modernize the interventional lab with...
Stereotaxis Announces FDA Clearance and Launch of Synchrony System
ST. LOUIS, April 06, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has r...
Stereotaxis Proxy statement: Proxy filing
Stereotaxis filed a proxy statement on April 3, 2026, providing details for shareholder voting and corporate governance matters.
Stereotaxis Proxy statement: Proxy filing
Stereotaxis filed a proxy statement on April 3, 2026, providing details for shareholder voting and corporate governance matters.
Stereotaxis files $100M mixed securities shelf
16:26 EDT Stereotaxis (STXS) files $100M mixed securities shelf